Business, energy, technology, markets and global industry news from Business News Today

Cushing’s syndrome

PharmaDeviceNews Cushing’s syndrome
Representative image: Corcept Therapeutics has resubmitted the relacorilant New Drug Application for Cushing’s syndrome, reopening FDA scrutiny of efficacy, trial design and liver safety evidence.
Pharma & Biotech

Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains

Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.

Read More
Representative image of clinical diabetes data review, highlighting Corcept’s Korlym findings in hypercortisolism-linked type 2 diabetes and GLP-1 treatment outcomes.
Pharma & Biotech

Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease

Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.

Read More
Medical Devices & Diagnostics

Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial

Corcept's MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.

Read More
Pharma & Biotech

Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage

Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.

Read More